NGEN.US NervGen Pharma Corp.

Healthcare Biotechnology USA Stocks
1.88 USD
Close of Nov 15, 2026
1.28 6.30
Market cap
USD 202M
P/E
-
P/B
16.68x
ROE
-366.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NGEN.US undervalued?

Graham number

The Graham number of NervGen Pharma Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NervGen Pharma Corp. fundamental analysis

No fundamental analysis for NervGen Pharma Corp. yet.

NervGen Pharma Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NervGen Pharma Corp.

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyot…

Full company profile